As the company is punished for its failure to diversify, could it be forced into making an acquisition?
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.